T

op of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with a favorite that has the aroma of Jack Daniel’s Tennessee Whiskey. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Several former Insys Therapeutics (INSY) defendants derided “inflammatory” charges filed against them by the federal government in a filing that seeks to dismiss the case, according to this document filed in federal court in Boston. Prosecutors rely on “ugly insinuation about lawful business practices” used to promote the Subsys nasal spray, which contains the fentanyl painkiller. The former executives were accused of running a scheme that involved a sham speaker program and bribing doctors in order to boost prescriptions.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy